Long-Term Pulmonary Damage in Surviving Antitoxin-Treated Mice following a Lethal Ricin Intoxication.

antitoxin intranasal long-term damage ricin

Journal

Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765

Informations de publication

Date de publication:
12 Feb 2024
Historique:
received: 13 12 2023
revised: 30 01 2024
accepted: 08 02 2024
medline: 23 2 2024
pubmed: 23 2 2024
entrez: 23 2 2024
Statut: epublish

Résumé

Ricin, a highly potent plant-derived toxin, is considered a potential bioterrorism weapon due to its pronounced toxicity, high availability, and ease of preparation. Acute damage following pulmonary ricinosis is characterized by local cytokine storm, massive neutrophil infiltration, and edema formation, resulting in respiratory insufficiency and death. A designated equine polyclonal antibody-based (antitoxin) treatment was developed in our laboratory and proved efficacious in alleviating lung injury and increasing survival rates. Although short-term pathogenesis was thoroughly characterized in antitoxin-treated mice, the long-term damage in surviving mice was never determined. In this study, long-term consequences of ricin intoxication were evaluated 30 days post-exposure in mice that survived antitoxin treatment. Significant pulmonary sequelae were demonstrated in surviving antitoxin-treated mice, as reflected by prominent histopathological changes, moderate fibrosis, increased lung hyperpermeability, and decreased lung compliance. The presented data highlight, for the first time to our knowledge, the possibility of long-term damage development in mice that survived lethal-dose pulmonary exposure to ricin due to antitoxin treatment.

Identifiants

pubmed: 38393180
pii: toxins16020103
doi: 10.3390/toxins16020103
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Yoav Gal (Y)

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 74100, Israel.

Anita Sapoznikov (A)

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 74100, Israel.

Shlomi Lazar (S)

Department of Pharmacology, Israel Institute for Biological Research, Ness-Ziona 74100, Israel.

David Shoseyov (D)

Pediatric Pulmonology Unit, Hadassah Medical Center, Jerusalem P.O. Box 12000, Israel.

Moshe Aftalion (M)

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 74100, Israel.

Hila Gutman (H)

Department of Pharmacology, Israel Institute for Biological Research, Ness-Ziona 74100, Israel.

Yentl Evgy (Y)

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 74100, Israel.

Rellie Gez (R)

Department of Pharmacology, Israel Institute for Biological Research, Ness-Ziona 74100, Israel.

Reinat Nevo (R)

Department of Biomolecular Sciences, Weizmann Institute of Science, Herzel 234, Rehovot P.O. Box 26, Israel.

Reut Falach (R)

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 74100, Israel.

Classifications MeSH